NASDAQ$SCPH

scPharmaceuticals Inc · Q4 2016 earnings

Q4 2016 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.47

No prior period
Net Income

-$5.32M

No prior period
Operating Income

-$3.96M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$3.02M

No prior period

Revenue & EPS history

scPharmaceuticals · Revenue · Quarterly

$16M

Q2 2025+99.2%vs Q2 2024
Beat estimate in 7 of 10 quarters(70%)
ActualEstimate

Revenue by segment

scPharmaceuticals · $3.8M total across 1 segment · Q3 2023

  • FUROSCIX
    $3.8M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 7 quarterly earnings reports

Historical avg

+3.8%

Avg return

Earnings day

+5.8%

Avg return

5 days after

+7.1%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+52.7%

Q4 2019

Best reaction

-14.5%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025-7.4%-4.6%+11.6%
Q1 2025+27.4%+45.1%+74.8%
Q4 2024-1.0%-1.3%-15.5%
Q3 2024-14.5%-14.8%-18.6%
Q2 2024+2.6%+3.7%+11.8%
Q1 2024+5.1%+10.6%-6.9%
Q4 2023-1.1%+2.2%-7.8%
Q3 2023-8.4%
Q2 2023+0.0%
Q1 2023-0.6%
Q4 2022+25.0%
Q3 2022+7.3%
Q2 2022+8.6%
Q1 2022+7.7%
Q4 2021+7.0%
Q3 2021-10.1%
Q2 2021+4.9%
Q1 2021-5.3%
Q4 2020-6.6%
Q3 2020+2.0%
Q2 2020+0.0%
Q1 2020-4.0%
Q4 2019+52.7%
Q3 2019-5.4%
Q2 2019+10.1%
Q1 2019+0.6%
Q4 2018-4.8%
Q3 2018+1.2%
Q2 2018+2.9%
Q1 2018+29.2%
Q4 2017-6.7%
Q3 2017
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro